A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerability and Maximum Tolerated Dose of Oral AP24534 in Patients with Refractory or Advanced Chronic Myelogenous Leukemia and other Hematologic Malignancies (AP24534-07-101)

Trial Profile

A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerability and Maximum Tolerated Dose of Oral AP24534 in Patients with Refractory or Advanced Chronic Myelogenous Leukemia and other Hematologic Malignancies (AP24534-07-101)

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Jun 2017

At a glance

  • Drugs Ponatinib (Primary)
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Chronic myeloid leukaemia; Haematological malignancies
  • Focus Adverse reactions
  • Sponsors ARIAD Pharmaceuticals
  • Most Recent Events

    • 01 Jun 2017 Status changed from active, no longer recruiting to completed.
    • 06 Dec 2016 Results of pooled analysis (n=76, data cut-off-2 Feb 2015) of a subgroup of chronic phase -chronic myelogenous leukemia patients from the phase 1 (NCT00660920) and pivotal phase 2 PACE (NCT01207440) trials, presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top